Avalyn Pharma Inc. (AVLN)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-05-05

Key Insights

FMR LLC (Fidelity) converted 2.28 million shares of preferred stock into common stock on May 1, 2026, in connection with Avalyn Pharma's IPO, indicating a major institutional investor transition from private to public ownership.
FMR LLC holds a significant 10% beneficial ownership stake in AVLN through indirect ownership via F-Prime Capital Partners Healthcare Fund V LP, establishing it as a major shareholder in the newly public company.
The conversion involved five different preferred stock series (A, B, C-1, C-2, and D) all converting on a 1-for-1 basis, reflecting a standard IPO capitalization restructuring with no apparent dilution or preferential treatment.
As a Director and 10% owner, FMR LLC has both governance influence and substantial financial stake in Avalyn Pharma's success, though the filing disclaims admission of beneficial ownership per standard SEC language.

Insider Trading Filed: 2026-05-05

Key Insights

Novo Holdings A/S, a 10% owner and director of Avalyn Pharma, acquired 555,555 common shares at $18 per share on 05/01/2026, demonstrating continued investment commitment during or around the company's IPO period.
The filing documents the automatic conversion of 63.0 million preferred shares (Series A through D) into approximately 3.3 million common shares on a 1-for-19.2417 basis upon IPO closing, reflecting standard IPO conversion mechanics and establishing Novo Holdings' substantial post-IPO ownership position.
Novo Holdings' total beneficial ownership reached 3.88 million voting common shares following these transactions, indicating a significant strategic stake in the newly public company with continued confidence in its valuation and prospects.

Current Report Filed: 2026-05-01

Key Insights

Avalyn Pharma completed its initial public offering (IPO) with the filing of an Amended and Restated Certificate of Incorporation, marking the company's transition to a public company with shares trading on Nasdaq under ticker AVLN.
The company authorized a substantial capital structure with 700 million total shares (500 million voting and 200 million non-voting common stock) plus 10 million undesignated preferred shares, providing significant flexibility for future financing and strategic transactions.
The updated governance documents establish standard public company procedures including stockholder meeting protocols, advance notice requirements for director nominations, and board nomination procedures, reflecting the company's transition from private to public status.
As an emerging growth company, Avalyn Pharma has elected to use the extended transition period for new accounting standards, which allows more time to comply with accounting rule changes applicable to larger filers.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.